Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
MMTZF · OTC · United States · Pharmaceutical Preparations
In shortMindMaze Therapeutics Holding SA is loss-making, burns cash and holds more cash than debt, with revenue shrinking (−11.0% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -1751.4% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -1551.5% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -99.4% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -185.3% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.65× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.01× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -116.78× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -285.4% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 3 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 3 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 2 | 17/100 |
| Revenue growth volatility | 49.0% | 0/100 |
| Operating margin volatility | 579.6% | 0/100 |
Weight in the score: 20%
Fiscal year 2023 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
The last 3 fiscal years from the company's annual reports.
CHF millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 |
|---|---|---|---|
| Revenue | 4.5 | 7.1 | 6.3 |
| Research & development | 19 | 12 | 1.3 |
| Operating income | (34) | (52) | (111) |
| Interest expense | 1.3 | 2.3 | 0.9 |
| Pre-tax income | (36) | (54) | (112) |
| Income tax | (0.8) | (3.5) | (14) |
| Net income | (35) | (51) | (98) |
| Diluted EPS | −CHF0.01 | −CHF4.81 | −CHF8.35 |
| Diluted shares (millions) | 3,593 | 11 | 12 |
Not computed: a required balance-sheet item is missing.
3/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2023 · Data updated Apr 30, 2024